Clinical Trials - April 4, 2017
Ascendis Pharma presents new data
Ascendis Pharma has announced data supporting its product pipeline presented at ENDO 2017, the annual meeting of the Endocrine Society in Orlando, Florida. “We are delighted to show the breadth of our growing pipeline at this year’s ENDO conference, including three potentially differentiated treatments for rare endocrine diseases,” said Jonathan Leff, M.D., Chief Medical Officer […]
Clinical Trials - December 2, 2014
Ascendis Fundraising for Trial
Danish biotech Ascendis Pharma has put together a $60 million D round, cash that will help get its once-a-week treatment for growth hormone deficiency (GHD) into late-stage testing. Ascendis is relying on a technology called TransCon, a hydrogel made of prodrug linkers that seek out targeted molecules in the body and then release their dosage.The […]
Clinical Trials - September 16, 2014
Ascendis Pharma A/S announces positive results from phase II study
The Danish biotechnology company Ascendis Pharma A/S has announced positive interim results from its ongoing Phase 2 pediatric study. The study regards evaluating once-weekly TransCon Growth Hormone in children with growth hormone deficiency, or GHD. “It has been demonstrated that patients who do not comply with the daily injection regimen of currently available growth hormone therapies suffer from […]
In a new job - June 2, 2014
Ascendis Pharma appoints new CEO
Danish biotechnology company Ascendis Pharma has appointed Martin Auster, M.D., as Chief Business Officer. Dr. Auster joins the company from United Therapeutics, where he has served as Vice President, Business Development. Prior to United Therapeutics, Dr. Auster held positions in the investment banking industry, including as a Senior Biotechnology Analyst at Wachovia Securities and a Senior Analyst/Healthcare-focused […]
